Company Filing History:
Years Active: 2022
Title: Xiangguo Gu: Innovator in Biomedicine
Introduction
Xiangguo Gu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biomedicine, particularly through his innovative work on monoclonal antibodies. His research focuses on improving therapeutic options for diseases related to angiogenesis.
Latest Patents
Xiangguo Gu holds a patent for an anti-VEGFR-2 monoclonal antibody. This invention provides an improved anti-Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) monoclonal antibody and its applications. The patent describes a novel phage antibody library designed through computer-aided simulation, leading to the development of an improved antibody after multiple rounds of screening. The resulting antibody exhibits higher affinity and biological activity compared to the original version. It effectively inhibits the combination of VEGFR-2 and its ligand, Vascular Endothelial Growth Factor (VEGF), in vitro. This advancement has potential applications in treating tumors and diseases caused by angiogenesis, such as macular degeneration.
Career Highlights
Xiangguo Gu is associated with Beijing Dongfang Biotech Co., Ltd., where he continues to advance his research in biomedicine. His work has garnered attention for its potential impact on therapeutic strategies in oncology and ophthalmology.
Collaborations
Xiangguo Gu collaborates with Yi Bai, contributing to the innovative research environment at Beijing Dongfang Biotech Co., Ltd. Their partnership enhances the development of cutting-edge biopharmaceuticals.
Conclusion
Xiangguo Gu is a notable inventor whose work in developing an improved anti-VEGFR-2 monoclonal antibody showcases his commitment to advancing biomedicine. His contributions have the potential to significantly impact the treatment of various diseases.